Arteriovenous Plasma Multiomics in Patients With Disorders of Consciousness
1 other identifier
observational
100
1 country
1
Brief Summary
In order to determine the abnormal cerebral metabolism in the pathological state, we compared the blood of internal jugular vein, superior vena cava and radial artery during central venous catheterization. Metabonomics, proteomics and inflammatory factor microarray were used to detect the material differences in arteriovenous blood of patients with disorders of consciousness. At the same time, we concurrently compared it with the peripheral plasma metabolome of two additional patient cohorts: those in-stent restenosis and non-restenosis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
March 14, 2022
CompletedStudy Start
First participant enrolled
May 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 30, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2024
CompletedFirst Posted
Study publicly available on registry
May 7, 2024
CompletedMay 7, 2024
March 1, 2022
1.9 years
March 14, 2022
May 6, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Patient clinical outcome
The patients were followed up for 12 months after blood collection to observe the clinical outcome
12 months
Study Arms (4)
Minimally conscious state (MCS)
Minimally conscious state (MCS): have reproducible signs of awareness and exhibit fluctuations in consciousness
Vegetative state (VS)
Vegetative state (VS): can open their eyes and preserve sleep-wake cycles, but unaware of themselves and their surroundings
Patients with In-Stent Restenosis
In-Stent Restenosis was defined as greater than 50% within or immediately adjacent (within 5 mm) to the stent implanted that was detected by digital subtraction angiography (DSA).
Patients with Non-Restenosis
In-Stent Restenosis was defined as less than 50% within or immediately adjacent (within 5 mm) to the stent implanted that was detected by digital subtraction angiography (DSA).
Interventions
No intervention
Eligibility Criteria
Patients with consciousness disorder caused by various severe brain injuries were recruited at Intensive care unit of The First Affiliated Hospital of Zhejiang University and Intensive care unit of the Second Affiliated Hospital of Zhejiang University
You may qualify if:
- Patients with consciousness disorder caused by various severe brain injuries
You may not qualify if:
- Patients who have been judged brain dead
- There are persistent epileptic activity, inhibition or seizure inhibition patterns
- Recent fever, abnormal liver and kidney function
- Previous history of neurological or mental illness
- Have a history of tumor
- Inflammatory bowel diseases, hyperlipidemia, gastritis
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The First Affiliated Hospital of Zhejiang University
Hanzhou, Zhejiang, 310003, China
Biospecimen
Plasma for metabolites and lipids
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Target Duration
- 12 Months
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
March 14, 2022
First Posted
May 7, 2024
Study Start
May 1, 2022
Primary Completion
March 30, 2024
Study Completion
April 30, 2024
Last Updated
May 7, 2024
Record last verified: 2022-03
Data Sharing
- IPD Sharing
- Will not share